Zai Lab (ZLAB) Climbed, So What Is Driving Attention Now?

Zai Lab (ZLAB) is back in focus after early Phase 1b data for its lung cancer candidate zocilurtatug pelitecan, or zoci, presented at ESMO 2026, showed high response rates and a tolerable safety profile.

The zoci update arrived during a sharp move in Zai Lab’s shares. The latest 1-day share price return of 9.03% added to a 90-day share price return of 29.05% and a year-to-date share price gain of 38.66%. This came even though the 1-year total shareholder return declined 8.77% and the 5-year total shareholder return fell 76.99%, which points to improving short-term momentum alongside a much weaker long-run record.

Spot 21 high quality undiscovered gems that, like Zai Lab after this zoci readout, sit at the intersection of fresh clinical data and renewed market attention.

The share price now trades at a steep discount to both analyst targets and implied fair value, even after the zoci-driven bounce. Is that gap a sign of lingering caution, or an indication that Zai Lab’s pipeline risk is being mispriced?

Most Popular Narrative: 28% Undervalued

On the most followed valuation view, Zai Lab’s fair value of $33.30 sits well above the last close at $24.03, which creates a wide gap that the market is still debating.

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

See why 13 investors see Zai Lab as 28% undervalued.

Result: Fair Value of $33.30 (UNDERVALUED)

Still, the bullish Zai Lab narrative hinges on execution in a crowded China oncology market, as well as on geopolitical conditions that could disrupt cross border partnerships and trial pathways.

Find out about the key risks to this Zai Lab narrative.

Another Take On Zai Lab’s Valuation

On a simple sales multiple, Zai Lab trades on a P/S of roughly 6x, which looks low against the US biotech peer average of 11.1x yet high compared with a fair ratio of 3.4x. That split hints at both upside and downside risk. Which anchor do you trust more when sizing a position?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals across Zai Lab’s share price and valuation views can feel messy. Weigh the short-term bounce against the longer-term record and pressure points, then pressure test both sides of the story with 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zai Lab?

If Zai Lab has sharpened your focus on risk and reward, do not stop here. Cast a wider net across other thoughtfully filtered opportunities before the market moves first.

• Target steadier ride candidates by scanning 30 resilient stocks with low risk scores, which score well on resilience and seek to limit portfolio drawdowns when volatility picks up.
• Hunt for quality at a discount through the 28 high quality undervalued stocks and see which businesses combine solid fundamentals with prices that lag underlying metrics.
• Strengthen your core holdings using the list of solid balance sheet and fundamentals (24 results) to highlight companies that pair financial stability with room for future optionality.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com